ACTICOAT in action

Case Studies using ACTICOAT Wound Dressings

Less than a two week difference with ACTICOAT18After 6 weeks
Venous leg ulcer

ACTICOAT used as primary dressing in conjunction with compression bandaging on a long standing venous leg ulcer. Treatment plan of twice-weekly bandage changes due to high levels of exudate

 Leg ulcer at first wound dressing change

Wound progressing after the first dressing change

 Leg Ulcer after 6 weeks ACTICOAT treatment

After 6 weeks ACTICOAT was discontinued as the wound bed was now not infected
A two week difference with ACTICOAT Moisture Control19After 4 weeks
Diabetic foot ulcer

Type 2 diabetic with extensive partial-thickness skin loss. Wound at initial presentation after debridement. Other leg previously amputated following complications arising from infected neuropathic ulcer

 Diabetic foot ulcer at wound dressing change

Wound at time of dressing change

 Diabetic foot ulcer after 4 weeks ACTICOAT treatment

Diabetic Foot Clinic follow-up visit, four weeks after initial presentation
A two week difference - ACTICOAT Flex 320ALLEVYN◊ Gentle Border used as secondary dressing
Colonised surgical wound

Heavily colonised malodorous surgical wound left to heal by secondary intention. Wound had been present for eight months and the patient complained of odour and discharge

 ACTICOAT wound dressing used on surgical wound

Improvement after just two weeks using ACTICOAT Flex 3

 Silver wound dressing effect on surgical wound

Following just a few weeks, all the signs and symptoms of infection had disappeared and the wound continued to follow a normal wound healing trajectory

Change the outcome, take the ACTICOAT 2 WEEK CHALLENGE◊.

Apply to receive a 2 week's supply of ACTICOAT Flex* samples for appropriate use on an infected wound.

 

*Where possible samples will be ACTICOAT Flex, in areas where ACTICOAT Flex is not registered an alternative ACTICOAT variant may be offered.

References

  1. Kelly J. Addressing the problem of increased antibiotic resistance. Prof Nurs 2001; 17(1): 56-9
  2. Hamilton-Miller JMT, Shah S, Smith C. Silver sulphadiazine: a comprehensive in-vitro reassessment. Chemotherapy 1993; 39: 405-9
  3. Maillard J-Y and Denyer SP. 2006. Focus on Silver. EWMA JournalV6(1)
  4. Warriner R and Burrell R. Infection and the chronic wound - a focus on silver. Advances in Skin and Wound Care Vol 18 (Supp. 1) Oct 2005
  5. Chopra I. (2007) The increasing use of silver based products as antimicrobial agents: a useful development or a cause of concern. Journal of Antimicrobial Chemotherapy 59, 587-590
  6. Vlachou E, et al. The safety of nanocrystalline silver dressings on burns: A study of systemic absorption. Burns 2007. 33(8):979-85
  7. Sibbald R G, Browne A C, Coutts P, Queen D, 'A Screening Evaluation of an Ionized Nanocrystalline Silver Dressing in Chronic Wound Care'. Ostomy Wound Management 2001; 47(10): 38-4
  8. Gago M, et al., A comparison of three silver-containing dressings in the treatment of infected, chronic wounds. Wounds 2008; 20 (10): 273-278
  9. Wright JB, et al. 'Wound Management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment', American Journal of Infection Control 1998; 26(6): 572-577 
  10. Smith & Nephew Data on File; 0810016 
  11. Smith & Nephew Data on File; 0810017 
  12. Hope R, et al., (2012) The in-vitro antibacterial activity of nanocrystalline silver dressings against bacteria withNDM-1 carbapenemase. Poster at EWMA, Austria, 2012. 
  13. Smith & Nephew Data on File WRP-TW141-022 
  14. Westain Report Ref: #971030
  15. World Union of Wound Healing Societies (WUWHS). Principles of best practice: Wound infection in clinical practice. An international consensus. London: MEP Ltd, 2008. Available from www.woundsinternational.com  
  16. International consensus. Appropriate use of silver dressings in wounds. An expert working group consensus. London: Wounds International, 2012.Available from:www.woundsinternational.com 
  17. Searle and Bielby (2010) Dressing strategies for the management of infected wounds in community wound care: impacts and implications. Poster at Wounds UK, Harrogate Nov 2010.
  18. Murray, S and Pardoe, A (2010) Making an Impact: Improving the patient experience using ACTICOAT Flex. Case Study Booklet 
  19. Tongue G., Prytherch J., Harvey A. The Silver Revolution. Exeter Primary Care Trust. Poster Presentation. Wounds UK. Harrogate 2004 
  20. Bowering K. “ACTICOAT Moisture Control. A New Clinical Option” Case study presentation. Satellite Symposium at Stuttgart (a joint meeting for ETRS, EWMA and DGfW) 2005

Try it today

Infected Wounds

Change
the outcome

Try it today

Proven effective on infected chronic wounds in two weeks*

  • * ACTICOAT has been shown in a clinical trial to eliminate all signs and symptoms of wound infection within 2 weeks in 60% of cases Gago M, et al., Wounds 2008; 20(10): 273-278
  • ** ACTICOAT has been shown to kill MRSA within 30 minutes in vitro (Wright et al, AJIC 2008 (26) 572-7)
  • ◊ Trade mark Smith & Nephew.
  • This information is intended for Healthcare professionals. In particular if you are viewing this from the U.S. please visit our dedicated professionals website.

Select Country

Canada flag
Canada UK
Australia flag New Zealand
Australia New Zealand
German flag
Germany Spain
Brazil

 Latin America
Rest of World

 
Rest of World